Macrophages can alternate between two states: an inflammatory state for fighting infection and a non-inflammatory state for ...

Silent Crohn’s disease' is a form of inflammatory bowel disease that may develop without typical or obvious symptoms.

Ontunisertib could become the first FDA-approved anti-fibrotic suitable for Crohn’s disease patients with symptomatic ...

STENOVA trial achieves primary endpoint in 103 study participants after 12 weeks of treatment -- -- Pharmacokinetic results confirm gut-restricted profile of ontunisertib in FSCD patients -- -- ...

Scientists at the University of Oxford, have identified how rare populations of abnormal cells drive the formation and ...

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...

UC San Diego researchers combined artificial intelligence with molecular biology to unravel how immune cells in the gut ...

Tyruko ® (natalizumab-sztn), a biosimilar to Tysabri ® (natalizumab), has been made available by Sandoz, according to developer Polpharma Biologics.

Artificial intelligence helps UCSD scientists discover a biological process connected to the bowel disease, potentially ...

Thanks to COVID-era discussions, the 2023 coverage of a Delta passenger who had diarrhea in their seat (I cannot imagine), ...

The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...

Patients with refractory Crohn’s disease who previously received ustekinumab experienced clinical and endoscopic improvements ...